Back to results
US 2022/0090040 A1Published application
Fusion Constructs for Controlling Protein Function
AssigneeSenti Biosciences, Inc.
InventorsDaniel Frimannsson, Philip Janmin Lee, Timothy Kuan-Ta Lu, Russell Morrison Gordley
Life of this patent
Estimating the term…
Abstract
Described herein are engineered fusion proteins comprising a variant protease (e.g., an HCV NS3 protease) fused to a polypeptide of interest and a cognate protease cleavage site. The cleavability of the cognate protease cleavage site enables the controllability of one or more functions of the polypeptide of interest. Additionally disclosed are methods for generating engineered fusion proteins as well as their therapeutic use.
Claims60
A fusion protein, comprising:
- a polypeptide of interest;
- a variant hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease;
- and
- a cognate protease cleavage site,
- wherein the variant HCV NS3 protease comprises one or more mutations;
- and
- wherein the one or more mutations decrease immunogenicity when the fusion protein is expressed in a mammalian cell.
4 more elements
Dependencies are inferred from the claim text.